8-K: DocGo Announces Q1 2025 Results, Adjusts Full-Year Guidance Due to Government Population Health Uncertainty

DocGo reports a decline in Q1 revenue due to the wind-down of migrant-related programs and revises its full-year guidance to reflect uncertainty in the Government Population Health vertical.

Summary

• DocGo announced its Q1 2025 financial results, reporting total revenue of $96.0 million, a decrease from $192.1 million in Q1 2024, primarily due to the planned wind-down of migrant-related programs.
• The company's GAAP gross margin was 28.2%, compared to 32.8% in the same period last year, while the adjusted gross margin was 32.1%, down from 35.0% in Q1 2024.
• DocGo reported a net loss of $11.1 million for the quarter, compared to a net income of $10.6 million in Q1 2024.
• Adjusted EBITDA loss was $3.9 million, a significant decrease from the $24.1 million adjusted EBITDA in the first quarter of 2024.
• Due to policy changes and public spending adjustments affecting the Government Population Health vertical, DocGo has revised its full-year 2025 revenue guidance to $300-$330 million, down from the previous estimate of $410-$450 million.
• The company now expects a full-year 2025 adjusted EBITDA loss of $20-$30 million, compared to the previous expectation of a 5% adjusted EBITDA margin.
• DocGo repurchased 1.95 million shares of common stock during the quarter for approximately $5.8 million.
• As of March 31, 2025, DocGo held $103.1 million in cash and cash equivalents.

Sentiment

Score: 4

Explanation: The sentiment is slightly negative due to the significant decrease in revenue and the revised guidance indicating a loss for the year. However, management's plans to cut costs and pursue M&A opportunities provide some optimism.

Positives

• DocGo's Medical Transportation and Payer & Provider businesses are performing in line with expectations and are on a solid growth trajectory.
• The company completed a record number of medical transports during the quarter.
• Care gap closure visit volumes are approaching three times the amount from the same time last year.
• DocGo generated $9.7 million of cash flow from operations compared to cash used in operations of $10.6 million in the first quarter of 2024.
• The company plans to aggressively cut SG&A over the next several quarters.
• DocGo anticipates positive cash flow through the balance of the year driven by collections of outstanding migrant-related receivables.
• The company plans to utilize its strong balance sheet to grow both organically and through M&A.
• DocGo signed a contract with a major New York health plan to offer DocGo Primary Care services.
• DocGo surpassed 900,000 patients assigned for care gap closure services.
• A two-year contract was signed with the North Texas division of a national health system for medical transportation services.
• The company experienced a record quarter for its medical transportation segment in terms of revenue and trip volume.
• DocGo signed a one-year contract that expands the company's relationship with a California-based cardiology group.

Negatives

• Total revenue decreased from $192.1 million in Q1 2024 to $96.0 million in Q1 2025.
• GAAP gross margin decreased from 32.8% in Q1 2024 to 28.2% in Q1 2025.
• Adjusted gross margin decreased from 35.0% in Q1 2024 to 32.1% in Q1 2025.
• The company reported a net loss of $11.1 million in Q1 2025, compared to a net income of $10.6 million in Q1 2024.
• Adjusted EBITDA loss was $3.9 million in Q1 2025, compared to adjusted EBITDA of $24.1 million in Q1 2024.
• Full-year 2025 revenue guidance was revised down from $410-$450 million to $300-$330 million.
• Full-year 2025 adjusted EBITDA is now expected to be a loss of $20-$30 million, compared to the previous expectation of a 5% adjusted EBITDA margin.
• Mobile Health Services revenue decreased from $143.9 million in Q1 2024 to $45.2 million in Q1 2025.

Risks

• Ongoing policy changes in Washington and adjustments to public spending on healthcare-related projects have created substantial uncertainty in the Government Population Health vertical.
• The company's future performance is subject to risks related to the accelerated wind down of migrant-related services.
• Uncertainties exist related to future non-migrant municipal population health revenue.
• The company's ability to return to profitability and/or expand its programs with insurance partners, hospital systems, municipalities and other strategic partners is not guaranteed.
• The company's ability to successfully implement its business strategy is subject to various risks.
• The company's reliance on government contracts, including changes in government spending on healthcare and other social services, poses a risk.
• Overall macroeconomic and geopolitical conditions, including the interest rate environment, the inflationary environment, the potential recessionary environment, regional conflict and tensions, financial institution instability and the prospect of a shutdown of the U.S. federal government, could impact the company's performance.

Future Outlook

Full-year 2025 revenue is expected to be $300-$330 million. Full-year 2025 adjusted EBITDA is now expected to be a loss of $20-$30 million. The company plans to aggressively cut SG&A and anticipates positive cash flow through the balance of the year. DocGo also plans to utilize its strong balance sheet to grow both organically and through M&A.

Management Comments

• 'The impact of ongoing policy changes in Washington and adjustments to public spending on healthcare-related projects have created substantial uncertainty in our Government Population Health vertical at the federal, state and local levels,' said Lee Bienstock, Chief Executive Officer of DocGo.
• Bienstock stated that the company has decided to remove all non-migrant Government Population Health revenue and any related projections from its 2025 guidance.
• Bienstock emphasized that the revision is driven by the Government Population Health vertical, while the Hospital and Payer & Provider verticals continue to perform in line with expectations.
• Norm Rosenberg, Chief Financial Officer of DocGo, commented that the company plans to aggressively cut SG&A over the next several quarters and anticipates positive cash flow through the balance of the year.
• Rosenberg added that DocGo plans to utilize its strong balance sheet to take advantage of opportunities being presented by the current market uncertainty to grow both organically and through M&A.

Industry Context

The announcement reflects the challenges faced by healthcare providers relying on government contracts, particularly in the context of changing policies and public spending. The shift away from migrant-related programs and the focus on medical transportation and payer/provider businesses indicate a strategic adjustment to navigate the evolving healthcare landscape.

Comparison to Industry Standards

• Given the shift in focus away from government contracts, DocGo's performance should be compared to companies primarily focused on medical transportation and mobile health services within the private sector.
• Companies like American Medical Response (AMR) and Acadian Ambulance Service are key competitors in the medical transportation space, and DocGo's growth in this segment should be benchmarked against their performance.
• In the mobile health services sector, companies like Teladoc Health and Amwell offer remote patient monitoring and virtual care, and DocGo's expansion in care gap closure programs and virtual care management should be evaluated in comparison to these industry leaders.
• DocGo's adjusted EBITDA margin, now projected to be negative, lags behind industry leaders in both medical transportation and telehealth, which typically aim for double-digit EBITDA margins.

Stakeholder Impact

• Shareholders will be impacted by the decreased revenue and adjusted EBITDA guidance, potentially leading to a decline in stock price.
• Employees may be affected by the planned SG&A cuts.
• Customers in the Government Population Health vertical may experience changes in service due to the company's strategic shift.
• Suppliers may be impacted by the company's cost-containment measures.
• Creditors will be monitoring the company's ability to maintain positive cash flow and manage its debt.

Next Steps

• Aggressively cut SG&A over the next several quarters.
• Focus on growing Medical Transportation and Payer & Provider businesses.
• Utilize strong balance sheet to grow both organically and through M&A.
• Continue enhancing the company's tech stack to improve transportation turnaround times and address search functionality.

Key Dates

Keywords

DocGo, financial results, earnings, revenue, EBITDA, mobile health, medical transportation, government population health, migrant services, guidance, Q1 2025